Angel Biotechnology is to increase its contracted work for ReNeuron Group, the life sciences company conducting stem cell trials at Glasgow’s Southern General Hospital.
Edinburgh-based Angel said it would expand production of drugs and testing materials under the new contract, scheduled for completion in the current financial year.
Chairman Nicholas Smith said: “The new contract will demonstrate Angel’s ability to provide high-quality, reliable and value-for-money services.”
Aim-quoted Angel has complained of difficult market conditions this year and in September announced it was relocating staff between its three sites to respond to opportunities for growth.
ReNeuron said last month that its stem cell trial was progressing to plan, with stroke patients benefiting observably from the treatment without any negative side effects.